All News

In prior studies, higher levels of physical activity were associated with higher prevalence of coronary artery calcium.

Data from the PERSEUS trial supports use of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone followed by daratumumab and lenalidomide maintenance as a new standard of care for patients with newly diagnosed multiple myeloma.

Adults who did not report past 3-day electronic nicotine delivery system use did not have an increased risk of asthma incidence.

Evidence indicates that up to 25% of all prescriptions for children could be dosed inappropriately, making it the most common type of medication administration error.

Results from the initial safety run-in of MajesTEC-7 indicate that the combination of teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma (NDMM) shows a manageable safety profile with early signs of efficacy.

The study showed that belantamab mafodotin plus pomalidomide and dexamethasone (BPd) significantly improved progression-free survival compared to pomalidomide plus bortezomib and dexamethasone (PVd).

The PALOMA-3 trial showed subcutaneous amivantamab was better than IV for lung cancer patients.

Asciminib demonstrated stronger efficacy, safety, and tolerability, as well as less adverse events in patients compared with those who received investigator-selected standard-of-care tyrosine kinase inhibitors.

Daratumumab in combination with standard treatment regimens shows benefit in multiple myeloma.

Patients with sickle cell disease with more than a 6-month delay transitioning from pediatric to adult care were about twice as likely to be hospitalized.

Promises of sexual improvement may ensnare unsuspecting patients with potentially dangerous adverse effects from untested OTC remedies.

Data analysis can help hospitals address waste of controlled substances that fuels diversion and increased costs.

Data presented at ASCO 2024 show fam-trastuzumab deruxtecan-nxki (T-DXd) delayed cancer growth in patients with hormone receptor-positive (HR+), HER2-low or -ultralow disease that progressed following endocrine therapy (ET).

The phase 3 LAURA trial data presented at ASCO 2024 showed osimertinib (Tagrisso; AstraZeneca) reduced risk of disease progression or death in patients with stage 3 EGFR-mutated (EGFRm) non–small cell lung cancer (NSCLC) by 84%.

Results from the trial provide evidence bolstering ASCO’s clinical practice guideline supporting the integration of early palliative care into standard oncology practice.

Matthew A. Gubens, MD, MS, FASCO, highlights the importance of identifying genetic targets in metastatic non–small cell lung cancer (NSCLC), emphasizing the latest updates and strategies.

Understanding patients’ specific experiences and challenges is crucial to helping them improve medication adherence.

This is the largest dataset of pregnancy outcomes for an anti-CD20 therapy in MS, enabling a more comprehensive understanding of ocrelizumab’s safety.

The addition of ribociclib (Kisqali; Novartis) to endocrine therapy demonstrated a 28% risk reduction in invasive disease-free survival.

In addition to medication management, pharmacists are educating patients and helping them navigate the complex medical system.

The priority review of inavolisib is for treatment of patients with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Although this data seems to overwhelmingly suggest that cannabis use has negative impacts for individuals with multiple sclerosis (MS), listening to patients’ reasoning for using it is crucial.

Women who received epidural analgesia during labor were less likely to experience severe maternal morbidity complications, such as heart attack or heart failure and sepsis.

This is Moderna's second mRNA vaccine approval and the first mRNA vaccine approved for an indication other than COVID-19.

Quadruple therapies including immunotherapy agents show promise in treating patients with multiple myeloma.

Subcutaneous ocrelizumab can be delivered in approximately 10 minutes and deliver comparable clinical benefit and safety to the IV formulation.

The study compares the safety and efficacy of mRNA-1345 compared to placebo.